While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

The Voice features host Gloria Burns in a meaningful conversation with Roxie Soto from the Leukemia & Lymphoma Society (LLS) to highlight the organization’s mission, patient support programs, ...

Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

Life changes post-diagnosis included early retirement due to immune compromise and personal milestones like adopting a new ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...